Speciality Medicines IPO GMP: Day 1 IPO Live Updates

Thu Mar 19 2026

The Speciality Medicines IPO GMP is ₹0 as of 20th March 2026. It is an IPO bookbuild issue of ₹29.14 crores. This is an entirely fresh Issue of 29.14 crore shares. The issue will be listed on BSE and SME on its tentative listing date, 30th March 2026. The face value of Speciality Medicines IPO shares is ₹10 per share, and the IPO price band is ₹117 to ₹124 per share. Retail investors can bid for a minimum of 2 lots of 2,000 shares worth ₹2,48,000.

Table of Contents

Speciality Medicines IPO Grey Market Premium

As of 20th March 2025, the GMP for the Speciality Medicines IPO stands at ₹0.00 per share. Thus, the estimated listing price would be ₹146.00. This indicates that the estimated listing gain in this IPO could be 0.00%. However, GMP details are subject to change in response to market conditions and fluctuations. Explore the table for the Speciality Medicines IPO GMP updates.

GMP DATE	IPO Price	GMP Price	Estimated Listing Price	Estimated Gain
20-3-2026	₹124.00	₹0.00	₹124.00	0.00%
19-3-2026	₹124.00	₹0.00	₹124.00	0.00%
18-3-2026	₹124.00	₹0.00	₹124.00	0.00%
17-3-2026	₹124.00	₹0.00	₹124.00	0.00%
16-3-2026	₹124.00	₹0.00	₹124.00	0.00%

Click & Sign Up to Get Latest Updates on Speciality Medicines IPO

Speciality Medicines IPO Details

IPO Allotment Date	25th March 2026
IPO Open Date	20th March 2026
IPO Close Date	24th March 2026
Refund Initiation	27th March 2026
Issue Size	23,50,000 shares(agg. up to ₹29 Cr
Face Value	₹10 per share
Lot Size	1,000 shares
Issue Price	₹117 to ₹124 per share
Issue Type	Bookbuilding IPO
Listing At	BSE & SME
Listing Date	30th March 2026

Explanation

Speciality Medicines IPO: Speciality Medicines IPO Limited has declared an issue price band of ₹117 to ₹124 per share. With this IPO, the company allows retail investors to bid for at least 2 lots of 2,000 shares, each worth ₹2,48,000. The face value of Speciality Medicines IPO Limited shares is ₹10 per share. The shares of Speciality Medicines IPO Limited will be listed on BSE and SME on its tentative listing day, 30th March 2026. Scroll down to check GMP updates and Speciality Medicines IPO reviews.

Objectives of the Speciality Medicines IPO

The primary aim of the Speciality Medicines IPO is to raise ₹29.14 crores, and the secondary objective is to:

The company will not receive any proceeds from the offer.
Product Registration in International Markets and Product Development for sale in international markets
To Meet Working Capital Requirements
General Corporate Purposes

Speciality Medicines IPO Registrar

Skyline Financial Services Limited is the registrar for the Speciality Medicines IPO, awaiting the allotment process and initiating refunds. For any queries regarding the Speciality Medicines allotment and refund, you can contact Skyline Financial Services Private Limited at ipo@skylinerta.com or 02228511022.

Speciality Medicines IPO Review

The Speciality Medicines IPO has gained neutral ratings from industry experts, brokers, and institutional investors. Speciality Medicines Limited’s revenue increased by 23.01%, from ₹58.54 crore in March 2024 to ₹36.93 crore in March 2025. Moreover, the company’s PAT increased by 32.52% from ₹8.61 crore in March 2024 to ₹6.06 crore in March 2025.

Most analysts recommend applying for this IPO to diversify your investment portfolio. However, we’re waiting for further ratings to gain a better understanding and will continue to post them to deliver real-time insights. Until then, you can explore the company’s technical analysis to know whether you should apply for the Speciality Medicines IPO or not.

Technical Analysis

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Speciality Medicines IPO.

Key Indicators	Value
PE Ratio (Price-to-Earnings)	9.27
EPS (Earnings Per Share)	13.38
RoNW	16.61%
ROCE	16.68%
ROE	16.49%
EBITDA Margin	17.73%
Price to Book Value	2.19
Market Capitalisation	₹108.94

The P/E ratio of Speciality Medicines Limited shares is 9.27, and its Earnings Per Share (EPS) stands at 13.38/ Thus, the Speciality Medicines IPO can deliver gains on its tentative listing date, 30th March 2026.

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Speciality Medicines Limited are subject to change after the IPO. Explore the table below to get post-issue updates on these two metrics.

Indicators	Pre-IPO	Post-IPO
PE Ratio	9.27	10.49
EPS	13.38	11.82

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

FAQs on Speciality Medicines IPO

What is the GMP of the Speciality Medicines IPO?

Currently, on 20th March 2026, the Speciality Medicines IPO GMP (Grey Market Premium) stands at ₹124. This indicates that the estimated listing price could be ₹124.00 per share.

What is the issue price of the Speciality Medicines IPO?

The Speciality Medicines IPO price range is ₹117 to ₹124 per share. Retail investors can apply for a minimum of 2 lot, each consisting of 2,000 shares, worth ₹2,48,000. Moreover, HNIs are required to bid for a minimum of 15 lots (1,200 shares) worth ₹2,06,400.

Who is the registrar of the Speciality Medicines IPO?

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Speciality Medicines IPO, download the Speciality Medicines IPO RHP and Speciality Medicines IPO DRHP. Conduct thorough research before investing in IPOs to minimise the risk of significant losses. You can also consult your financial advisor.